Research Topics
Species | Charles RyanSummaryAffiliation: University of California Country: USA Publications
Research Grants
| Collaborators
|
Detail Information
Publications
Expression of insulin-like growth factor-1 receptor in local and metastatic prostate cancerCharles J Ryan
Department of Medicine, UCSF Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA 94115, USA
Urol Oncol 25:134-40. 2007..Despite this targeting, there are conflicting data on the presence of this receptor in human tumor samples, largely because of differences in technique...
Targeted MET inhibition in castration-resistant prostate cancer: a randomized phase II study and biomarker analysis with rilotumumab plus mitoxantrone and prednisoneCharles J Ryan
University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA 94115, USA
Clin Cancer Res 19:215-24. 2013....- Abiraterone acetate for the treatment of prostate cancerCharles J Ryan
Genitourinary Medical Oncology, UCSF Helen Diller Family Comprehensive Cancer Center, 1600 Divisadero Street, San Francisco, CA 94115, USA
Expert Opin Pharmacother 14:91-6. 2013..Significant areas of scientific investigation remain in the optimization and further understanding of the therapy... - Abiraterone in metastatic prostate cancer without previous chemotherapyCharles J Ryan
Genitourinary Medical Oncology Program, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA 94115, USA
N Engl J Med 368:138-48. 2013..We evaluated this agent in patients who had not received previous chemotherapy... 
Isolation and genomic analysis of circulating tumor cells from castration resistant metastatic prostate cancerMark Jesus M Magbanua
Department of Medicine, Division of Hematology Oncology, University of California San Francisco, USA
BMC Cancer 12:78. 2012..However, it is the molecular characterization of CTCs that offers insight into the biology of these tumor cells in the context of personalized treatment...- Adrenal androgen levels as predictors of outcome in prostate cancer patients treated with ketoconazole plus antiandrogen withdrawal: results from a cancer and leukemia group B studyCharles J Ryan
Urologic Oncology Program, University of California, San Francisco, California 94143, USA
Clin Cancer Res 13:2030-7. 2007..Ketoconazole is used as an inhibitor of adrenal androgen synthesis in men with androgen-independent prostate cancer. This study analyzes the relationship between pretreatment androgen levels and outcome following ketoconazole treatment... - Phase I dose escalation and pharmacokinetic study of AZD2171, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinase, in patients with hormone refractory prostate cancer (HRPC)Charles J Ryan
Urologic Oncology Program, UCSF Comprehensive Cancer Center, 1600 Divisadero 3rd Floor, San Francisco, CA, USA
Invest New Drugs 25:445-51. 2007..While further study is indicated, careful attention must be paid to the novel toxicities of this agent with prolonged dosing... - Initial treatment patterns and outcome of contemporary prostate cancer patients with bone metastases at initial presentation: data from CaPSURECharles J Ryan
Department of Medicine, University of California at San Francisco Comprehensive Cancer Center, University of California at San Francisco, San Francisco, California 94143, USA
Cancer 110:81-6. 2007.... - Prostate specific antigen only androgen independent prostate cancer: natural history, challenges in management and clinical trial designCharles J Ryan
Department of Medicine and University of California San Francisco Comprehensive Cancer Center, University of California San Francisco, San Francisco, California 94143, USA
J Urol 178:S25-9. 2007..A consensus panel was convened to review data and propose a strategy for trial design and prioritization... - Phase II study of ketoconazole plus granulocyte-macrophage colony-stimulating factor for prostate cancer: effect of extent of disease on outcomeCharles J Ryan
Urologic Oncology Program, University of California San Francisco Comprehensive Cancer Center, University of California San Francisco, San Francisco, California 94115, USA
J Urol 178:2372-6; discussion 2377. 2007..The efficacy of ketoconazole plus the immunostimulatory cytokine granulocyte-macrophage colony-stimulating factor was prospectively evaluated in patients with castration resistant prostate cancer with and without metastases... - A pilot dose-escalation study of the effects of nordihydroguareacetic acid on hormone and prostate specific antigen levels in patients with relapsed prostate cancerCharles J Ryan
Department of Medicine and the corrected UCSF Comprehensive Cancer Center, University of California San Francisco, CA 94143, USA
BJU Int 101:436-9. 2008.... - Inhibitory effects of nordihydroguaiaretic acid (NDGA) on the IGF-1 receptor and androgen dependent growth of LAPC-4 prostate cancer cellsCharles J Ryan
Department of Medicine, University of California, San Francisco, California 94143, USA
Prostate 68:1232-40. 2008..The current study evaluates the effect of NDGA on the androgen-stimulated growth of human prostate cancer cells... - The selection of hormonal therapy in prostate cancer: who, when, and for how long?Charles J Ryan
Department of Medicine, UCSF Comprehensive Cancer Center, University of California San Francisco, 1600 Divisadero St, San Francisco, CA 94143, USA
J Natl Compr Canc Netw 2:261-8. 2004.... - Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapyCharles J Ryan
Urologic Oncology Program, University of California, San Francisco, San Francisco, CA 94115, USA
J Clin Oncol 28:1481-8. 2010..This phase I dose-escalation study of abiraterone acetate evaluated safety, pharmacokinetics, and effects on steroidogenesis and prostate-specific antigen (PSA) levels in men with CPRC with or without prior ketoconazole therapy... - Androgen receptor rediscovered: the new biology and targeting the androgen receptor therapeuticallyCharles J Ryan
UCSF Helen Diller Family Comprehensive Cancer Center, 1600 Divisadero St, San Francisco, CA 94115, USA
J Clin Oncol 29:3651-8. 2011..The clinical success of therapies that directly target androgen synthesis as well as the most common aberrancies of the AR confirm that prostate cancer retains dependence on AR signaling, even in the castrate state... - Androgen deprivation therapy in locally advanced and metastatic prostate cancerC J Ryan
Department of Medicine and UCSF Comprehensive Cancer Center, University of California, San Francisco, CA 94143, USA
Minerva Urol Nefrol 58:119-26. 2006..In virtually all analyses, patients with high-risk features benefited from early AD when compared to deferred therapy. Consideration of AD is therefore warranted early in the clinical course of high-risk patients... - The case for secondary hormonal therapies in the chemotherapy ageEric J Small
Urologic Oncology Program, UCSF Comprehensive Cancer Center, University of California San Francisco, 1600 Divisadero Street, San Francisco, CA 94115, USA
J Urol 176:S66-71. 2006..Despite this fact numerous therapies are available that target the interaction of androgen and androgen receptor in the castrate testosterone milieu and many clinical investigations are under way in this area... - High risk biochemical relapse and the timing of androgen deprivation therapyCharles J Ryan
Department of Medicine and UCSF Comprehensive Cancer Center, University of California San Francisco, 1600 Divisadero Street, San Francisco, CA 94115, USA
J Urol 176:S61-5. 2006..We offer guidance on its use in patients with prostate specific antigen recurrence only... - Early versus delayed androgen deprivation for prostate cancer: new fuel for an old debateCharles J Ryan
UCSF Comprehensive Cancer Center, 1600 Divisadero St, San Francisco CA 94143, USA
J Clin Oncol 23:8225-31. 2005..Consideration of AD is therefore warranted early in the clinical course of high-risk patients... - Prostate cancer update: 2005Charles J Ryan
Department of Medicine and UCSF Comprehensive Cancer Center, University of California, San Francisco, CA 94143, USA
Curr Opin Oncol 18:284-8. 2006..The purpose of this review is to highlight the most important developments in the diagnosis, prevention, and management of prostate cancer that have been published in the medical literature in the past year... - Phase II study of abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer displaying bone flare discordant with serologic responseCharles J Ryan
Genitourinary Medical Oncology Program, UCSF Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, California 94115, USA
Clin Cancer Res 17:4854-61. 2011.... - Angiogenesis inhibition plus chemotherapy for metastatic hormone refractory prostate cancer: history and rationaleCharles J Ryan
Urologic Oncology Program, UCSF Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA 94143, USA
Urol Oncol 24:250-3. 2006..This review will highlight the clinical experience to date with angiogenesis inhibitors in prostate cancer and the ongoing studies... - Progress in detection and treatment of prostate cancerCharles J Ryan
Department of Medicine, UCSF Comprehensive Cancer Center, University of California, San Francisco, California, USA
Curr Opin Oncol 17:257-60. 2005..The purpose of this review is to highlight the most important developments in the diagnosis, prevention, and management of prostate cancer reported in the past year that have been published in the medical literature... - Chemotherapy for hormone-refractory prostate cancer: now it's a question of "when?"Charles J Ryan
UCSF Comprehensive Cancer Center, Box 1711, 1600 Divisadero St, San Francisco, CA 94115, USA
J Clin Oncol 23:8242-6. 2005..In this review, we will highlight some of the issues that impact on the decision of when to start chemotherapy and in whom as well as the potential benefits of secondary hormonal approaches... - Secondary hormonal manipulations in prostate cancerCharles J Ryan
Urologic Oncology Program, UCSF Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA 94115, USA
Hematol Oncol Clin North Am 20:925-34. 2006..Novel agents are being developed that seek to prolong the duration of clinical responses and the overall response rate... - Reduced incidence of bony metastasis at initial prostate cancer diagnosis: data from CaPSURECharles J Ryan
Department of Medicine, and UCSF Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA 94143, USA
Urol Oncol 24:396-402. 2006..This study describes features that characterize patients with M+ compared to those diagnosed with M0 disease... - Role of secondary hormonal therapy in the management of recurrent prostate cancerCharles J Ryan
Urologic Oncology Program, University of California San Francisco Comprehensive Cancer Center, University of California San Francisco, San Francisco, California 94143, USA
Urology 62:87-94. 2003..This article reviews the clinical trial data for these various agents and discusses their role in the management of patients with advanced prostate cancer... - Secondary hormonal manipulations in prostate cancerCharles J Ryan
Urologic Oncology Program, University of California at San Francisco Comprehensive Cancer Center, 1600 Divisadero Street, 3rd Floor, San Francisco, CA 94143, USA
Curr Oncol Rep 7:228-33. 2005..Collectively, the modest activity of these therapies challenges the notion that advancing prostate cancer will uniformly become "hormone refractory.".. - Abiraterone acetate for castration resistant prostate cancerShreya Shah
UCSF, Division of Hematology and Oncology, Department of Medicine, 1600 Divisadero St, Box 1711, San Francisco, CA 94115, USA
Expert Opin Investig Drugs 19:563-70. 2010..The toxicity profile has also been found to be acceptable. Two large Phase III clinical trials are currently open to accrual and will hopefully validate the impressive Phase II data... - Five-year outcomes after neoadjuvant chemotherapy and conformal radiotherapy in patients with high-risk localized prostate cancerCharles J Ryan
Genitourinary Oncology Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA
Urology 64:90-4. 2004..These long-term findings support the continued study of chemotherapy combined with RT as a potential alternative to prolonged androgen deprivation... - Advances in prostate cancerCharles J Ryan
Urologic Oncology Program, UCSF Comprehensive Cancer Center, University of California San Francisco, San Francisco, California 94143, USA
Curr Opin Oncol 16:242-6. 2004..The purpose of this review is to highlight the most important developments in the diagnosis, prevention, and management of prostate cancer reported in the past year that have been published in the medical literature... - Chemotherapy for good-risk germ-cell tumorsCharles J Ryan
Genitourinary Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan-Kettering Cancer Center, Joan and Sanford I. Weill Medical College of Cornell University, New York, NY 10021, USA
Semin Urol Oncol 20:244-50. 2002..Bleomycin remains controversial in good-risk germ-cell tumors, but the literature suggests that both E(500)P for four cycles or BE(500)P for three cycles may be considered standard... - Novel concepts in androgen receptor blockadeAndrew C Hsieh
The Urologic Oncology Program, UCSF Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA 94143, USA
Cancer J 14:11-4. 2008..These include direct androgen receptor inhibitors, inhibitors of adrenal androgen synthesis, and a dual 5alpha-reductase isoenzyme inhibitor... - Intermittent chemotherapy for metastatic hormone refractory prostate cancerAmy M Lin
UCSF Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA 94115, USA
Crit Rev Oncol Hematol 61:243-54. 2007.... - Persistent prostate-specific antigen expression after neoadjuvant androgen depletion: an early predictor of relapse or incomplete androgen suppressionCharles J Ryan
Genitourinary Oncology Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA
Urology 68:834-9. 2006..Whether this represents a failure to abrogate androgen receptor mediated signaling with androgen depletion or early reactivation of signaling is under study... - A phase II trial of imatinib mesylate in patients with biochemical relapse of prostate cancer after definitive local therapyAmy M Lin
University of California/San Francisco, San Francisco, CA 94115, USA
BJU Int 98:763-9. 2006.... - Phase II evaluations of cilengitide in asymptomatic patients with androgen-independent prostate cancer: scientific rationale and study designKathleen W Beekman
Genitourinary Oncology Service, Division of Hematology-Oncology, Department of Internal Medicine, University of Michigan Comprehensive Cancer Center, Ann Arbor, 48109, USA
Clin Genitourin Cancer 4:299-302. 2006.... - A phase I trial of docetaxel/estramustine/imatinib in patients with hormone-refractory prostate cancerAmy M Lin
UCSF Comprehensive Cancer Center, University of California, San Francisco, CA 94115, USA
Clin Genitourin Cancer 5:323-8. 2007..Imatinib inhibits the platelet-derived growth factor receptor that is expressed in prostate cancer and is synergistic with taxanes in preclinical prostate cancer models... - Androgen-response elements in hormone-refractory prostate cancer: implications for treatment developmentAndrew C Hsieh
Department of Medicine, and UCSF Comprehensive Cancer Center, University of California San Francisco, 94143, USA
Lancet Oncol 8:933-9. 2007..We discuss the effects of bona-fide downstream targets of the androgen receptor on cellular proliferation, evasion of apoptosis, and angiogenesis, and consider the clinical potential of these targets... - Novel therapeutic strategies in development for prostate cancerAndrea L Harzstark
University of California, Department of Medicine, Box 1711, San Francisco, 1600 Divisadero Street, San Francisco, CA 94115, USA
Expert Opin Investig Drugs 17:13-22. 2008..This review will highlight recent and current studies for many of the promising developments for advanced disease, as well as novel early stage approaches... - Therapies in development for castrate-resistant prostate cancerAndrea L Harzstark
Department of Medicine, University of California, San Francisco, 1600 Divisadero Street, Box 1711, San Francisco, CA 94115, USA
Expert Rev Anticancer Ther 8:259-68. 2008..This review will highlight the promise of these new approaches and the challenges to their development... - High BAALC expression associates with other molecular prognostic markers, poor outcome, and a distinct gene-expression signature in cytogenetically normal patients younger than 60 years with acute myeloid leukemia: a Cancer and Leukemia Group B (CALGB) stChristian Langer
Division of Hematology and Oncology, Department of Internal Medicine, Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210, USA
Blood 111:5371-9. 2008..We conclude that high BAALC expression is an independent adverse prognostic factor and is associated with a specific gene-expression profile... - Innovations and challenges in prostate cancer: summary statement for the 6th Cambridge ConferencePhilip W Kantoff
Lank Center for Genitourinary Oncology, Boston, Massachusetts, USA
J Urol 178:S5-8; quiz S4. 2007
Research Grants
- Targeting Androgen -IGF Interactions in Prostate CancerCharles Ryan; Fiscal Year: 2007....